A nonsteroidal antiestrogen, tamoxifen was repurposed and approved for treatment of metastatic breast cancer and later for breast cancer risk reduction, and is currently the standard of care for long-term adjuvant therapy for estrogen receptor-positive breast cancer [69]. The gene discussed is ESR1; the disease is breast carcinoma.